X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

Fact Check Friday: The truth about biopharmaceutical patents

By Mark Grayson  |    August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines,...   Read More

Canada’s promise doctrine strikes again

By Mark Grayson  |    May 26, 2016
In just the last few weeks Canada has once again taken steps to invalidate yet another medicine (Zymar®) by applying the “promise doctrine.” See Allergan Inc. v. Apotex Inc., 2016 FC 344 (April 1,...   Read More

Strong IP is propelling innovation and saving lives

By Mark Grayson  |    May 5, 2016
Each day, new medicines are being researched and developed that save lives and improve patients’ quality of life. As the global epicenter of life science innovation and technological...   Read More

World IP Day: Celebrating the protections that allow innovation to thrive

By Mark Grayson  |    April 26, 2016
Today is World Intellectual Property Day, a celebration across the globe of the protections that allow creativity, risk-taking and innovation to thrive. America has long been the world’s innovation...   Read More

India denies patent on novel HIV/AIDS medicine

By Mark Grayson  |    April 14, 2016
In 2014, several months after Prime Minister Modi took office, he announced an ambitious initiative called “Make in India.” The goal was to encourage foreign and domestic companies to manufacture...   Read More

IP protections found to be critical to life-science innovation and investment

By Jay Taylor  |    April 7, 2016
A new report by the Information Technology and Innovation Foundation (ITIF) has found intellectual property (IP) protections to be crucial to stimulating risk-taking and innovation. The study, How...   Read More

Time to enforce the rules that protect American ideas, brands and inventions

By Chris Moore  |    March 1, 2016
Earlier today, PhRMA joined organizations representing every sector of America’s knowledge economy at a public hearing in Washington that will inform the federal government’s annual “Special 301”...   Read More

Time for Canada to catch up on intellectual property

By Mark Grayson  |    February 18, 2016
Last week, the U.S. Chamber of Commerce’s Global Intellectual Property Center (GIPC) released its fourth annual International IP Index. The Index, which measures the intellectual property (IP)...   Read More

Canada’s innovation opportunity

By Jay Taylor  |    February 11, 2016
Next month’s visit of Prime Minister Justin Trudeau to Washington is a chance to strengthen a vital trade and investment partnership and to resolve problems left over by Canada’s previous...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."